AB-LIFE probiotic formulation has recently been approved by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, Anvisa) as a safe and efficient food supplement to help reduce cholesterol levels.
After reviewing in detail all clinical evidence behind the patented probiotic formulation, that included several in vitro, in vivo data and 5 clinical studies, Anvisa has stated that AB-LIFE can be sold in Brazil with the claim “The association of L. plantarum CECT 7527, L. plantarum CECT 7528 and L. plantarum CECT 7529 can help reduce cholesterol levels”
AB-LIFE contains 3 probiotic strains with clinically proven effects on cholesterol and triglyceride levels
This is the first probiotic with an approved claim in dyslipidemia in Brazil, leading the innovation of the sector and hopefully opening the door to other products. The approval conditions include a once a day, 12-week minimum posology, and no contra-indications or warnings.
The approval was granted thanks to the AB-BIOTICS team hard work, and with the collaboration of Meta Regulatória, a Brazilian consultancy agency specialized in regulatory issues of the region.
This approval sums up to others around the world, including regulatory approvals of Therapeutic Goods Administration, TGA (Australia) and Health Canada (Canada). Both supporting the use of AB-LIFE as a solution to reduce cholesterol levels. Plus, the product is recognised as safe by the US Food and Drug Administration, FDA, and the European Food and Safety Authority, EFSA